News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News ESC Heart Failure 2022 Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients Shelley Wood May 23, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News ESC Heart Failure 2022 Speech-Recognition Tool May Predict Worsening Congestion in HF Shelley Wood May 22, 2022
News Daily News ESC Heart Failure 2022 SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH Shelley Wood May 22, 2022
News Conference News EuroPCR 2022 MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients Michael O'Riordan May 20, 2022
News Conference News EuroPCR 2022 MitraClip Helps for Atrial Functional MR: MITRA-TUNE Michael O'Riordan May 19, 2022
News Daily News The Hunt for Protein Culprits in COVID-19’s Cardiac Complications Michael O'Riordan May 06, 2022
News Daily News Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis Caitlin E. Cox May 03, 2022
News Conference News HRS 2022 Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era Todd Neale May 02, 2022
News Daily News FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy Michael O'Riordan April 29, 2022
Presentation ARCH 2022 First Things First – Pharmacotherapy for HFrEF Presenter: Georges Chahoud April 23, 2022
Presentation ARCH 2022 Candidate Selection for Advanced Heart Failure Therapies: 2022 Presenter: Gregory Ewald April 23, 2022
News Daily News CVD Hospitalizations Spiked in Aftermath of 2020 US Election Michael O'Riordan April 22, 2022
News Daily News Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries Todd Neale April 20, 2022
News Daily News Revascularization’s Benefits in HFrEF Linked to Gains in LV Function Caitlin E. Cox April 15, 2022
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022